<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01578629</url>
  </required_header>
  <id_info>
    <org_study_id>2011H0242</org_study_id>
    <nct_id>NCT01578629</nct_id>
  </id_info>
  <brief_title>NUTRITION: Natural Tocotrienol Against Ischemic Stroke Event</brief_title>
  <acronym>NUTRITION</acronym>
  <official_title>Human Blood Outcomes Following Tocotrienol Supplementation - NUTRITION Phase I and Phase IIA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrew Slivka</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Government of Malaysia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A natural form of vitamin E called tocotrienol (TCT), found in many common foods such as&#xD;
      barley, decreases stroke size in animal models. Vitamin E has blood-thinning properties and&#xD;
      lowers cholesterol, which make it a potential therapy for stroke prevention, though these&#xD;
      effects are less well characterized for TCT. We plan to conduct two trials (I &amp; IIA) to&#xD;
      determine the effects of orally supplemented TCT on platelet function and cholesterol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A natural form of vitamin E called tocotrienol (TCT), found in many common foods such as&#xD;
      barley, decreases stroke size in animal models. Vitamin E has blood-thinning properties and&#xD;
      lowers cholesterol, which make it a potential therapy for stroke prevention, though these&#xD;
      effects are less well characterized for TCT. We plan to conduct two trials (I &amp; IIA) to&#xD;
      determine the effects of orally supplemented TCT on platelet function and cholesterol. Phase&#xD;
      I subjects will be healthy volunteers, recruited by an advertisement. Phase IIA subjects will&#xD;
      be hyperlipidemic (having high cholesterol), and will be referred to us by their Wound Care&#xD;
      Center Physicians. Patients will be randomized to receive placebo pills, (400 or 800 mg) TCT&#xD;
      pills, low-dose 81 mg aspirin (commonly used for secondary prevention of stroke), or TCT and&#xD;
      aspirin together. Potential subjects for Phase-I who meet study criteria and agree to&#xD;
      participate will be in the study for 6 months and have the following study related&#xD;
      procedures, blood draw total 4 times, tape stripping (non-invasive procedure), BMI, and blood&#xD;
      pressure measurement at each visit (every month). Participants in Phase-IIA will have blood&#xD;
      drawn a total of 6 times, tape stripping, BMI and blood pressure measurement and participants&#xD;
      will be in the study for 13 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">November 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet function panel</measure>
    <time_frame>up to one year</time_frame>
    <description>Blood draw followed by platelet aggregometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>up to one year</time_frame>
    <description>blood lipid panel including HDL, LDL, total cholesterol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tape Stripping Test</measure>
    <time_frame>up to one year</time_frame>
    <description>HPLC vitamin E analysis of tape strips for compliance</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Transient Ischemic Attack (TIA)</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy participants randomized into one of 6 groups that will take 4 capsules, twice a day of vitamin E tocotrienol (TCT) capsules ; Low Dose Aspirin or placebo capsule for 7 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperlipidemic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hyperlipidemic patients randomized into one of 6 groups that will take 4 capsules, twice a day of Vitamin E Tocotrienol (TCT) capsules; Low Dose Aspirin or placebo vehicle control capsule for 7 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin</intervention_name>
    <description>Vitamin E TCT capsules- 400-800 mg Aspirin- 81 mg</description>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Hyperlipidemic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo vehicle control</intervention_name>
    <description>vehicle control compared to Vitamin E TCT pills</description>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Hyperlipidemic</arm_group_label>
    <other_name>placebo capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Phase IA&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects between 40 and 70 years of age&#xD;
&#xD;
          -  No history of long-term vitamin E supplement (defined as daily oral tocopherol or&#xD;
             tocotrienol supplementation greater than or equal to 6mos; within the past 5 years)&#xD;
&#xD;
          -  No current vitamin E supplementation in multivitamin&#xD;
&#xD;
        Exclusion Criteria - (as self reported by potential participants during review of&#xD;
        eligibility criteria with Research Nurse,)&#xD;
&#xD;
          -  Evidence of heart disease as diagnosed by a physician by one or more of the following&#xD;
             tests; EKG, chest x-ray, stress test, tilt table test, echocardiogram, coronary&#xD;
             angiogram, electrophysiology test, CT heart scan, coronary MRI, pericardiocentesis&#xD;
&#xD;
          -  High cholesterol (total cholesterol &gt;240mg/dL, LDL&gt;160mg/dL)&#xD;
&#xD;
          -  Prior cancer diagnosis&#xD;
&#xD;
          -  Pregnancy - To exclude the possibility of pregnant women entering the study or&#xD;
             becoming pregnant during the study only post-menopausal women or women who have had&#xD;
             hysterectomies or bilateral oophorectomies will be included.&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Smoker (Must have quit 5 or more years ago)&#xD;
&#xD;
          -  Alcohol dependence (&gt;4 drinks per day for more than 1yr anytime in the last 3 years)&#xD;
&#xD;
          -  Medication exclusion criteria - current use or recent discontinuation (within last 28&#xD;
             days) of any medication including the following: anti-coagulants and blood-thinners&#xD;
             (e.g., Warfarin), psychotropic medications including antipsychotics, mood-stabilizers&#xD;
             (e.g., lithium, valproic acid, carbamazepine/tegretol); anti-depressants (tricyclics,&#xD;
             SSRI's, MAOI's, nonselective MAOIs, Wellbutrin, St. John's Wort);&#xD;
             anti-anxiety/anti-panic agents; anti-obsessive agents; prescription stimulants (e.g.,&#xD;
             Provigil, Ritalin); diet pills/anorectics; daily medication for chronic pain (e.g.,&#xD;
             opiates) or muscle spasms; daily use of over the counter stimulants in pill form&#xD;
             (e.g., ephedrine); daily medication for asthma, Parkinson's disease medications (e.g.,&#xD;
             levodopa, methyldopa, apomorphine), smoking cessation medications (Wellbutrin/Zyban,&#xD;
             Chantix/varenicline); statin use is not grounds for exclusion.&#xD;
&#xD;
        Phase IIA&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Hyperlipidemic patients between 40 and 70 years of age currently taking statins&#xD;
&#xD;
          -  LDL&gt;130mg/dL&#xD;
&#xD;
          -  TG&gt;150mg/dL&#xD;
&#xD;
          -  HDL&lt;40mg/dL&#xD;
&#xD;
          -  No history of long-term vitamin E supplement (defined as daily oral tocopherol or&#xD;
             tocotrienol supplementation greater than or equal to 6mos; within the past 5 years)&#xD;
&#xD;
          -  No current vitamin E supplementation in multivitamin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of heart disease as diagnosed by a physician by one or more of the following&#xD;
             tests; EKG, chest x-ray, stress test, tilt table test, echocardiogram, coronary&#xD;
             angiogram, electrophysiology test, CT heart scan, coronary MRI, pericardiocentesis&#xD;
&#xD;
          -  Prior cancer diagnosis&#xD;
&#xD;
          -  Currently taking blood thinners&#xD;
&#xD;
          -  Pregnancy - To exclude the possibility of pregnant women entering the study or&#xD;
             becoming pregnant during the study only post-menopausal women or women who have had&#xD;
             hysterectomies or bilateral oophorectomy will be included.&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Smoking (Must have quit within the past 6 months)&#xD;
&#xD;
          -  Alcohol dependence - (&gt;4 drinks per day for more than 1yr anytime in the last 3 years)&#xD;
&#xD;
          -  Medication exclusion criteria - current use or recent discontinuation (within last 28&#xD;
             days) of any medication including the following: anti-coagulants and blood-thinners&#xD;
             (e.g., Warfarin), psychotropic medications including antipsychotics, mood-stabilizers&#xD;
             (e.g., lithium, valproic acid, carbamazepine/tegretol); anti-depressants (tricyclics,&#xD;
             SSRI's, MAOI's, nonselective MAOIs, Wellbutrin, St. John's Wort);&#xD;
             anti-anxiety/anti-panic agents; anti-obsessive agents; prescription stimulants (e.g.,&#xD;
             Provigil, Ritalin); diet pills/anorectics; daily medication for chronic pain (e.g.,&#xD;
             opiates) or muscle spasms; daily use of over the counter stimulants in pill form&#xD;
             (e.g., ephedrine); daily medication for asthma, Parkinson's disease medications (e.g.,&#xD;
             levodopa, methyldopa, apomorphine), smoking cessation medications (Wellbutrin/Zyban,&#xD;
             Chantix/varenicline)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Ohio state University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 5, 2012</study_first_submitted>
  <study_first_submitted_qc>April 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2012</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Andrew Slivka</investigator_full_name>
    <investigator_title>MD, Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>ischemia</keyword>
  <keyword>TIA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

